Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Boston Veterans Affairs Healthcare System, Boston, Massachusetts; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington.
Am J Cardiol. 2014 Sep 15;114(6):843-8. doi: 10.1016/j.amjcard.2014.06.012. Epub 2014 Jul 1.
Plasma-free fatty acids (FFAs) are largely derived from adipose tissue. Elevated levels of FFA and fatty acid-binding protein 4 (FABP4), a key cytoplasmic chaperone of fatty acids, have been associated with adverse cardiovascular outcomes, but limited data are available on the relation of these biomarkers with cardiovascular and total mortality. We studied 4,707 participants with a mean age of 75 years who had plasma FFA and FABP4 measured in 1992 to 1993 as part of the Cardiovascular Health Study, an observational cohort of community-dwelling older adults. Over a median follow-up of 11.8 years, 3,555 participants died. Cox proportional hazard regression was used to determine the association between FFA, FABP4, and mortality. In fully adjusted models, FFA were associated with dose-dependent significantly higher total mortality (hazard ratio [HR] per SD: 1.14, 95% confidence interval [CI] 1.09 to 1.18), but FABP4 levels were not (HR 1.04, 95% CI 0.98 to 1.09). In a cause-specific mortality analysis, higher concentrations of FFA were associated with significantly higher risk of death because of cardiovascular disease, dementia, infection, and respiratory causes but not cancer or trauma. We did not find evidence of an interaction between FFA and FABP4 (p = 0.45), but FABP4 appeared to be associated with total mortality differentially in men and women (HR 1.17, 95% CI 1.08 to 1.26 for men; HR 1.02, 95% CI 0.96 to 1.07 for women, interaction p value <0.001). In conclusion, in a cohort of community-dwelling older subjects, elevated plasma concentrations of FFA, but not FABP4, were associated with cardiovascular and noncardiovascular mortality.
血浆游离脂肪酸(FFA)主要来源于脂肪组织。FFA 水平和脂肪酸结合蛋白 4(FABP4)升高与不良心血管结局相关,而关于这些生物标志物与心血管和全因死亡率的关系,数据有限。我们研究了 4707 名参与者,他们的平均年龄为 75 岁,在 1992 年至 1993 年期间作为社区居住的老年人观察队列心血管健康研究的一部分,测量了血浆 FFA 和 FABP4。在中位随访 11.8 年期间,有 3555 名参与者死亡。使用 Cox 比例风险回归来确定 FFA、FABP4 与死亡率之间的关系。在完全调整的模型中,FFA 与剂量依赖性的总死亡率显著升高相关(每标准差的风险比 [HR]:1.14,95%置信区间 [CI]:1.09 至 1.18),但 FABP4 水平没有(HR 1.04,95% CI:0.98 至 1.09)。在特定原因死亡率分析中,较高的 FFA 浓度与心血管疾病、痴呆、感染和呼吸系统原因导致的死亡风险显著升高相关,但与癌症或创伤无关。我们没有发现 FFA 和 FABP4 之间存在交互作用的证据(p = 0.45),但 FABP4 似乎在男性和女性的总死亡率方面存在差异(男性 HR 1.17,95% CI 1.08 至 1.26;女性 HR 1.02,95% CI 0.96 至 1.07,交互 p 值<0.001)。总之,在一个社区居住的老年人群体中,血浆 FFA 浓度升高,而不是 FABP4,与心血管和非心血管死亡率相关。